Method for sensitizing cancer cells to cancer therapies with a mevalonate-reducing compound
OwnerMing-Shi Shiaoinventor
Life of this patent
Estimating the term…
Abstract
The present invention provides a pharmaceutical kit useful for treating cancer cells in a mammal. Using this kit, the cancer cells are first sensitized by administering to the mammal an agent which comprises an effective amount of a HMG-CoA reductase inhibitor. The sensitized cancer cells are then treated with an anti-cancer agent which reduces the survival or growth of the cancer cells.
Claims22
A method for treating cancer cells in a mammal, comprising the steps of:
- (a) sensitizing said cancer cells by administering to the mammal an agent which comprises an effective amount of a HMG-CoA reductase inhibitor;
- and
- (b) treating the sensitized cancer cells with an anti-cancer agent which reduces the survival or growth of the cancer cells.
A nutraceutical composition which comprises oxygenated triterpenes extracted from pulverized Ganoderma fruiting bodies with methanol or a combination of ethanol and water.
A method of preparing a nutraceutical composition comprising oxygenated triterpenes comprising the step of extracting from pulverized Ganoderma fruiting bodies with methanol or a combination of ethanol and water at a elevated temperature to form a crude extract.
A method of treating a patient with cancer, comprising the steps of:
- (a) administrating to the patient a first agent which arrests the growth of cancer cells at a specific stage in the cell cycle to sensitize said cancel cells;
- and
- (b) administrating to the patient a second agent which can arrest the growth of said sensitized cancer cells at a later time point in the cell cycle as compared to the first agent.
Dependencies are inferred from the claim text.